Reactivation of p53 via MDM2 inhibition.
Division of Pediatric Surgery, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.
E S
ES
Kim
Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer Center, and Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
J M
JM
Shohet
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy*; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors*; D011759:Pyrrolidines / Q000494:pharmacology* / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D062366:para-Aminobenzoates / Q000494:pharmacology* / Q000627:therapeutic use
D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D011759:Pyrrolidines; C586849:RG7388; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A; D062366:para-Aminobenzoates; D051736:Proto-Oncogene Proteins c-mdm2